{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:16:44Z","timestamp":1787314604424,"version":"build-2736575974"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1164\/rccm.201806-1103ed","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T15:25:23Z","timestamp":1531754723000},"page":"1114-1116","source":"Crossref","is-referenced-by-count":1,"title":["Preservation of Lung Function in Cystic Fibrosis: Are Macrolides the Answer?"],"prefix":"10.1093","volume":"198","author":[{"given":"Andr\u00e9","family":"Schultz","sequence":"first","affiliation":[{"name":"Telethon Kids Institute, University of Western Australia,, Perth, Australia"},{"name":"Department of Respiratory Medicine, Perth Children\u2019s Hospital, Nedlands, Australia, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Sly","sequence":"additional","affiliation":[{"name":"Child Health Research Centre, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"2026032023265096000_bib1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/ppul.21374","article-title":"Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis","volume":"46","author":"Sanders","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"2026032023265096000_bib2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"2026032023265096000_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ppul.21601","article-title":"Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa","volume":"47","author":"Saiman","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"2026032023265096000_bib4","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for early Pseudomonas infection in cystic fibrosis: the OPTIMIZE randomized trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2026032023265096000_bib5","first-page":"CD012406","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032023265096000_bib6","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-2600(13)70185-1","article-title":"Long-term azithromycin for indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial","volume":"1","author":"Valery","year":"2013","journal-title":"Lancet Respir Med"},{"key":"2026032023265096000_bib7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jcf.2016.12.003","article-title":"Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis","volume":"16","author":"Nichols","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026032023265096000_bib8","doi-asserted-by":"crossref","first-page":"1800238","DOI":"10.1183\/13993003.00238-2018","article-title":"The clinical significance of oropharyngeal cultures in young children with cystic fibrosis","volume":"51","author":"Breuer","year":"2018","journal-title":"Eur Respir J"},{"key":"2026032023265096000_bib9","first-page":"CD002203","article-title":"Macrolide antibiotics for cystic fibrosis","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026032023265096000_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jcf.2015.02.006","article-title":"Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin","volume":"14","author":"Coolen","year":"2015","journal-title":"J Cyst Fibros"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/198\/9\/1114\/67120120\/ajrccm_198_9_1114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/198\/9\/1114\/67120120\/ajrccm_198_9_1114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:27:29Z","timestamp":1774063649000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/198\/9\/1114\/8498351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":10,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,11,1]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201806-1103ed","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,11,1]]}}}